Persones / Equip Humà

Mireia Camós Guijosa

Buscador de publicacions

Publicacions

  • Crespo M, Villamor N, Giné E, Muntañola A, Colomer D, Marafioti T, Jones M, Camós-Guijosa M, Campo E, Montserrat E and Bosch F.

    ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia

    CLINICAL CANCER RESEARCH . 12(3, 1): 726-734. Nº de cites: 39

    [doi:10.1158/1078-0432.CCR-05-1531]

  • Montoto S, López-Guillermo A, Altés A, Perea G, Ferrer A, Camós-Guijosa M, Villela L, Bosch F, Esteve J, Cervantes F, Bladé J, Nomdedeu B, Campo E, Sierra J and Montserrat E.

    Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression

    ANNALS OF ONCOLOGY . 15(10): 1484-1489. Nº de cites: 59

    [doi:10.1093/annonc/mdh406]

  • Rozman M, Camós-Guijosa M, Colomer D, Villamor N, Esteve J, Costa D, Carrió A, Aymerich M, Aguilar JL, Domingo A, Solé F, Gomis F, Florensa L, Montserrat E and Campo E.

    Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation

    GENES CHROMOSOMES & CANCER . 40(2): 140-145. Nº de cites: 64

    [doi:10.1002/gcc.20022]

  • Camós-Guijosa M, Esteve J, Rimola A, Grande L, Rozman M, Colomer D, Villamor N, Costa D and Montserrat E.

    Increased incidence of acute myeloid leukemia after liver transplantation? Description of three new cases and review of the literature

    TRANSPLANTATION . 77(2): 311-313. Nº de cites: 20

    [doi:10.1097/01.TP.0000102549.40531.13]

  • Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E, Alvarez-Larrán A, López-Jiménez J, Osorio S, Villalón L, Camós-Guijosa M, García-Conde J and Odriozola J.

    Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients

    HAEMATOLOGICA . 88(10): 1117-1122. Nº de cites: 38

  • Camós-Guijosa M, Arellano-Rodrigo E, Abelló D, Muntañola A, Ferrer A, Grau JM and Cervantes F.

    Idiopathic myelofibrosis associated with classic polyarteritis nodosa

    LEUKEMIA & LYMPHOMA . 44(3): 539-541. Nº de cites: 10

    [doi:10.1080/1042819021000046849]

  • Cervantes F, Hernández-Boluda JC, Odriozola J, Camós-Guijosa M, Villalón L, Martínez-Climent JA, del Campo R, García-Conde J and Montserrat E.

    Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation

    BRITISH JOURNAL OF HAEMATOLOGY . 120(3): 500-504. Nº de cites: 4

    [doi:10.1046/j.1365-2141.2003.04077.x]

  • Montoto S, López-Guillermo A, Ferrer A, Camós-Guijosa M, Alvarez-Larrán A, Bosch F, Bladé J, Cervantes F, Esteve J, Cobo F, Colomer D, Campo E and Montserrat E.

    Survival after progression in patients with follicular lymphoma: analysis of prognostic factors

    ANNALS OF ONCOLOGY . 13(4): 523-530. Nº de cites: 37

    [doi:10.1093/annonc/mdf119]

  • Alvarez-Larrán A, Villamor N, Hernández-Boluda JC, Ferrer A, Camós-Guijosa M, Campo E and López-Guillermo A.

    Blastic natural killer cell leukemia/lymphoma presenting as overt leukemia.

    Clinical Lymphoma . 2(3): 178-182. Nº de cites: 7

    [doi:10.3816/CLM.2001.n.024]

  • Montoto S, Camós-Guijosa M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E and Montserrat E.

    Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease

    CANCER . 88(9): 2142-2148. Nº de cites: 17

    [doi:10.1002/(SICI)1097-0142(20000501)88:9<2142::AID-CNCR21>3.0.CO;2-M]